Jefferies Reports on NXTM's Strong Growth

According to a recent report from Jefferies, the growth on NxStage Medical NXTM remains very good and although there are some concerns over the company's decision to approach CMS to get more reimbursement, Jefferies believes that NXTM is approaching CMS from a position of strength and not weakness. According to the report, Jefferies said, "Home is still profitable for most centers and patient additions remain healthy; NXTM is approaching CMS from a position of strength and not weakness." NxStage closed yesterday at $19.18.